Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epsin siRNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- Boston Children's Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Epsin siRNA nanoparticles (also referred to as S2PNP-siEpsin1/2) are an experimental nanomedicine platform designed to deliver small interfering RNAs (siRNAs) targeting Epsin 1 and Epsin 2. Epsins are endocytic adaptor proteins that, in the context of atherosclerosis, facilitate CD36-mediated lipid uptake and promote the degradation of the cholesterol transporter ABCG1 in macrophages. In the liver, Epsins contribute to PCSK9-mediated degradation of the low-density lipoprotein receptor (LDLR). By silencing Epsin 1 and Epsin 2 via RNA interference, these nanoparticles aim to reduce inflammation, enhance cholesterol efflux, and lower circulating LDL-C levels, thereby halting or reversing atherosclerotic plaque progression. The platform often utilizes a stabilin-2 targeting peptide (S2P) for macrophage-specific delivery or nanoparticle encapsulation for liver-directed therapy.
- Other names
- nanoparticle-encapsulated siRNAs targeting epsins 1 and 2macrophage-targeted epsin siRNA nanoparticles
02
Targets
EPN1 (Epsin-1)
Beyond the preview
Go deeper on epsin siRNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epsin siRNA nanoparticles.